These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 2647472)

  • 1. Effect of felbamate on phenytoin and carbamazepine serum concentrations.
    Graves NM; Holmes GB; Fuerst RH; Leppik IE
    Epilepsia; 1989; 30(2):225-9. PubMed ID: 2647472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Felbamate increases phenytoin but decreases carbamazepine concentrations.
    Fuerst RH; Graves NM; Leppik IE; Brundage RC; Holmes GB; Remmel RP
    Epilepsia; 1988; 29(4):488-91. PubMed ID: 3391153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate.
    Wagner ML; Graves NM; Marienau K; Holmes GB; Remmel RP; Leppik IE
    Epilepsia; 1991; 32(3):398-406. PubMed ID: 1904346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of felbamate on plasma levels of carbamazepine and its metabolites.
    Albani F; Theodore WH; Washington P; Devinsky O; Bromfield E; Porter RJ; Nice FJ
    Epilepsia; 1991; 32(1):130-2. PubMed ID: 1985822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of felbamate on carbamazepine and its major metabolites.
    Wagner ML; Remmel RP; Graves NM; Leppik IE
    Clin Pharmacol Ther; 1993 May; 53(5):536-43. PubMed ID: 8491065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coadministration of phenytoin and felbamate: evidence of additional phenytoin dose-reduction requirements based on pharmacokinetics and tolerability with increasing doses of felbamate.
    Sachdeo R; Wagner ML; Sachdeo S; Shumaker RC; Lyness WH; Rosenberg A; Ward D; Perhach JL
    Epilepsia; 1999 Aug; 40(8):1122-8. PubMed ID: 10448826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosage adjustments in response to monitored plasma concentrations: can unblinded staff adhere to objective criteria?
    Sahlroot JT; Pledger GW
    J Biopharm Stat; 1994 Mar; 4(1):91-100. PubMed ID: 8019586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compliant populations: variability in serum concentrations.
    Graves NM; Holmes GB; Leppik IE
    Epilepsy Res Suppl; 1988; 1():91-9. PubMed ID: 3072193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous assay of felbamate plus carbamazepine, phenytoin, and their metabolites by liquid chromatography with mobile phase optimization.
    Remmel RP; Miller SA; Graves NM
    Ther Drug Monit; 1990 Jan; 12(1):90-6. PubMed ID: 2305427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice.
    Gordon R; Gels M; Wichmann J; Diamantis W; Sofia RD
    Epilepsia; 1993; 34(2):367-71. PubMed ID: 8453946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of felbamate in children.
    Kelley MT; Walson PD; Cox S; Dusci LJ
    Ther Drug Monit; 1997 Feb; 19(1):29-36. PubMed ID: 9029743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous determination of felbamate, primidone, phenobarbital, carbamazepine, two carbamazepine metabolites, phenytoin, and one phenytoin metabolite in human plasma by high-performance liquid chromatography.
    Romanyshyn LA; Wichmann JK; Kucharczyk N; Shumaker RC; Ward D; Sofia RD
    Ther Drug Monit; 1994 Feb; 16(1):90-9. PubMed ID: 8160262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.
    Contin M; Riva R; Albani F; Baruzzi AA
    Ther Drug Monit; 1999 Dec; 21(6):604-8. PubMed ID: 10604819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiepileptic drugs in development: prospects for the near future.
    Leppik IE
    Epilepsia; 1994; 35 Suppl 4():S29-40. PubMed ID: 8174517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication.
    Duncan JS; Patsalos PN; Shorvon SD
    Epilepsia; 1991; 32(1):101-15. PubMed ID: 1985818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine-phenytoin interaction: elevation of plasma phenytoin concentrations due to carbamazepine comedication.
    Zielinski JJ; Haidukewych D; Leheta BJ
    Ther Drug Monit; 1985; 7(1):51-3. PubMed ID: 3992622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Felbamate: successful development of a new compound for the treatment of epilepsy.
    Schmidt D
    Epilepsia; 1993; 34 Suppl 7():S30-3. PubMed ID: 8243376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Felbamate: a clinical trial for complex partial seizures.
    Theodore WH; Raubertas RF; Porter RJ; Nice F; Devinsky O; Reeves P; Bromfield E; Ito B; Balish M
    Epilepsia; 1991; 32(3):392-7. PubMed ID: 2044501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Felbamate for partial seizures: results of a controlled clinical trial.
    Leppik IE; Dreifuss FE; Pledger GW; Graves NM; Santilli N; Drury I; Tsay JY; Jacobs MP; Bertram E; Cereghino JJ
    Neurology; 1991 Nov; 41(11):1785-9. PubMed ID: 1944909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of the EEG paroxysmal pattern during felbamate therapy in Lennox-Gastaut syndrome: a case report.
    Marciani MG; Spanedda F; Placidi F; Bassetti MA; Romigi A; Mattia D
    Int J Neurosci; 1998 Sep; 95(3-4):247-53. PubMed ID: 9777442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.